These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 15614152)

  • 1. Comparison between C0 and C2 monitoring in de novo renal transplant recipients: retrospective analysis of a single-center experience.
    Bîrsan T; Loinig C; Bodingbauer M; Wekerle T; Rockenschaub S; Berlakovich G; Soliman T; Mühlbacher F; Steininger R
    Transplantation; 2004 Dec; 78(12):1787-91. PubMed ID: 15614152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study.
    Kyllönen LE; Salmela KT
    Transplantation; 2006 Apr; 81(7):1010-5. PubMed ID: 16612277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
    Canadian Neoral Renal Transplantation Study Group
    Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
    Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine minimization and cost reduction in renal transplant recipients receiving a C2-monitored, cyclosporine-based quadruple immunosuppressive regimen.
    Hardinger KL; Schnitzler MA; Koch MJ; Enkvetchakul D; Desai N; Jendrisak M; Lowell JA; Miller B; Shenoy S; Brennan DC
    Transplantation; 2004 Oct; 78(8):1198-203. PubMed ID: 15502720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients.
    Solari SG; Goldberg LR; DeNofrio D; Shaw LM
    Ther Drug Monit; 2005 Aug; 27(4):417-21. PubMed ID: 16044096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-hour post-dose cyclosporine levels in renal transplantation in Argentina: a cost-effective strategy for reducing acute rejection.
    Balshaw R; Machnicki G; Carreño CA; Toselli L; Otero A; Keown PA
    Transplant Proc; 2005 Mar; 37(2):871-4. PubMed ID: 15848560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2).
    Levy G; Burra P; Cavallari A; Duvoux C; Lake J; Mayer AD; Mies S; Pollard SG; Varo E; Villamil F; Johnston A
    Transplantation; 2002 Mar; 73(6):953-9. PubMed ID: 11923699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of C0 and C2 cyclosporine monitoring in long-term renal transplant recipients.
    Marcén R; Pascual J; Tato A; Villafruela JJ; Teruel JL; Rivera ME; Tenorio M; Fernández M; Burgos FJ; Ortuño J
    Transplant Proc; 2003 Aug; 35(5):1780-2. PubMed ID: 12962793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month.
    Morris RG; Russ GR; Cervelli MJ; Juneja R; McDonald SP; Mathew TH
    Ther Drug Monit; 2002 Aug; 24(4):479-86. PubMed ID: 12142630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation.
    Barnard JB; Thekkudan J; Richardson S; Bittar MN; Martyszczuck R; Hasan J; Khasati N; Keevil B; Yonan N
    J Heart Lung Transplant; 2006 May; 25(5):564-8. PubMed ID: 16678036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation.
    Levy G; Villamil F; Samuel D; Sanjuan F; Grazi GL; Wu Y; Marotta P; Boillot O; Muehlbacher F; Klintmalm G;
    Transplantation; 2004 Jun; 77(11):1632-8. PubMed ID: 15201658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction.
    Cantarovich M; Giannetti N; Cecere R
    Clin Transplant; 2003 Apr; 17(2):144-50. PubMed ID: 12709082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
    Midtvedt K; Fauchald P; Bergan S; Høieggen A; Hallan S; Svarstad E; Bergrem H; Eriksen BO; Pfeffer PF; Dalen I; Leivestad T
    Transplantation; 2003 Oct; 76(8):1236-8. PubMed ID: 14578761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study.
    Iversen M; Nilsson F; Sipponen J; Eiskjaer H; Mared L; Bergan S; Nyström U; Fagertun HE; Solbu D; Simonsen S
    J Heart Lung Transplant; 2009 Sep; 28(9):919-26. PubMed ID: 19716045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine.
    Hecking M; Kainz A; Schillinger M; Posch C; Birsan T; Rasoul-Rockenschaub S; Böhmig GA; Schmaldienst S; Watschinger B; Hörl WH; Mühlbacher F; Säemann MD
    Transpl Int; 2008 Mar; 21(3):223-33. PubMed ID: 17903183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
    Caforio AL; Tona F; Piaserico S; Gambino A; Feltrin G; Fortina AB; Angelini A; Alaibac M; Bontorin M; Calzolari D; Peserico A; Thiene G; Iliceto S; Gerosa G
    Transpl Int; 2005 Jan; 18(1):116-24. PubMed ID: 15612993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.